Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to
treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The
goal is to extend the telomeres to prevent, delay, or even reverse the development of the
pathology of AD. It is expected to have a direct consequence on cognitive function and
quality of life in patients with neurodegenerative diseases, such as AD.